Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › NJ › Clifton › NPI 1932145778
Lab

Quest Diagnostics Incorporated

Quest Diagnostics Incorporated was paid $637.74M by Medicaid between Jan 2018 and Dec 2024, across 684 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 15% of everything it billed.

33Billing provider infoQUEST DIAGNOSTICS INCORPORATED
CLIFTON, NJ 07012
33aNPI1932145778assigned 06/21/2006
33bProvider typeClinical Medical Laboratory
28Total paid$637.74M
24GClaims57,184,397
24DCodes billed684
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other Clinical Medical Laboratory providers in New Jersey

Rank by total paid#2 of 122
Median peer was paid$1.29M
This provider vs. median496×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Auditor's notes

Automated statistical signals. Not evidence of fraud — how these are computed.

Entity ProliferationAuthorized official TIMMERMAN, LEAH controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service

Paid by month

$0$5.0M$10M$15M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
20185,700,102$55.32M
20196,910,070$66.02M
20206,832,048$96.48M
20218,861,043$124.67M
202210,011,823$109.50M
20239,998,091$94.73M
2024incomplete8,871,220$91.01M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r 15% 1,267,341 1,143,759 $95.01M
80307 Drug test(s), presumptive, any number of drug classes; immunoassay 5.0% 1,202,543 697,215 $32.17M
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe 5.0% 1,657,300 1,603,761 $31.67M
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe 4.9% 1,635,831 1,582,880 $30.95M
82306 Vitamin D; 25 hydroxy, includes fraction(s), if performed 3.4% 1,372,815 1,346,507 $21.80M
80061 Lipid panel 2.9% 2,911,844 2,864,674 $18.60M
80050 General health panel 2.8% 957,685 949,479 $17.65M
86480 2.7% 507,071 500,092 $17.21M
80053 Comprehensive metabolic panel 2.4% 2,795,608 2,709,453 $15.49M
86769 2.3% 402,695 399,860 $14.83M
84443 Thyroid stimulating hormone (TSH) 2.0% 1,626,303 1,596,772 $13.03M
87389 Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies 1.7% 895,936 880,014 $10.65M
672 more codes
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.7% 315,169 $10.60M
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe 1.6% 648,362 $10.24M
85025 Blood count; complete (CBC), automated, and automated differential WBC count 1.6% 2,769,243 $10.17M
83036 Hemoglobin; glycosylated (A1C) 1.5% 2,279,611 $9.84M
U0005 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 1.4% 429,034 $9.23M
87624 Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types 1.2% 399,794 $7.83M
81420 Fetal chromosomal aneuploidy genomic sequence analysis panel 1.1% 24,697 $6.70M
87801 Infectious agent detection by nucleic acid; amplified probe, multiple organisms 1.0% 200,865 $6.67M
81220 CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants 1.0% 29,409 $6.54M
82607 1.0% 835,243 $6.53M
86003 1.0% 137,113 $6.44M
87799 <1% 140,074 $6.05M
88175 Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer <1% 372,948 $5.69M
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 42,049 $5.50M
86803 <1% 724,964 $5.42M
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 101,540 $4.88M
82746 <1% 589,144 $4.36M
84439 <1% 941,811 $4.27M
87636 Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B <1% 34,395 $4.17M
81513 <1% 118,531 $4.13M
82728 <1% 587,131 $3.84M
87631 <1% 53,174 $3.82M
87086 Culture, bacterial; quantitative colony count, urine <1% 885,525 $3.73M
87340 <1% 669,845 $3.71M
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 86,863 $3.57M
84153 <1% 346,540 $3.18M
83013 <1% 88,143 $3.16M
81001 <1% 1,814,752 $3.07M
87536 <1% 59,839 $3.02M
83655 <1% 432,668 $2.98M
87070 <1% 571,680 $2.74M
84403 <1% 182,101 $2.64M
87088 <1% 542,530 $2.28M
86235 <1% 61,753 $2.22M
86317 <1% 265,597 $2.07M
83550 <1% 553,091 $2.05M
86762 <1% 249,210 $2.01M
80081 <1% 52,165 $1.99M
87512 <1% 108,720 $1.98M
86696 <1% 174,829 $1.97M
83540 <1% 659,167 $1.91M
86765 <1% 258,252 $1.89M
86592 <1% 785,538 $1.78M
86787 <1% 239,187 $1.66M
82670 <1% 106,287 $1.64M
86735 <1% 236,918 $1.64M
83001 <1% 158,754 $1.62M
84146 <1% 141,029 $1.58M
85027 <1% 523,874 $1.57M
86706 <1% 287,318 $1.56M
82652 <1% 114,750 $1.54M
87517 <1% 72,681 $1.51M
83002 <1% 148,612 $1.51M
86780 <1% 200,810 $1.50M
83970 <1% 78,727 $1.50M
88185 <1% 5,837 $1.43M
80074 <1% 75,874 $1.43M
82043 <1% 515,691 $1.43M
87481 <1% 59,044 $1.41M
84702 <1% 183,710 $1.37M
82570 <1% 549,412 $1.35M
84481 <1% 162,283 $1.35M
84402 <1% 94,166 $1.33M
86038 <1% 218,436 $1.30M
87081 <1% 370,284 $1.30M
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel <1% 9,591 $1.24M
86708 <1% 183,395 $1.20M
86704 <1% 196,829 $1.19M
87522 Neg quan hep c or qual rna <1% 53,540 $1.17M
87480 <1% 102,468 $1.12M
87510 <1% 102,396 $1.11M
86695 <1% 143,865 $1.10M
84480 <1% 207,452 $1.10M
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 54,553 $1.10M
87186 <1% 238,728 $1.09M
86360 <1% 39,204 $1.08M
88142 <1% 96,721 $1.03M
84436 <1% 393,572 $1.01M
82784 <1% 125,872 $997K
86376 <1% 128,486 $994K
87077 <1% 222,532 $979K
84550 <1% 425,255 $954K
G0145 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision <1% 74,950 $947K
88112 <1% 31,223 $940K
87660 <1% 103,282 $930K
80048 Basic metabolic panel (calcium, ionized) <1% 228,006 $924K
81329 <1% 24,630 $918K
86800 <1% 109,357 $917K
82248 <1% 362,056 $906K
82105 <1% 119,139 $902K
86618 <1% 90,866 $889K
82627 <1% 70,464 $862K
86617 <1% 54,360 $855K
84144 <1% 72,711 $822K
84154 <1% 83,005 $807K
83520 <1% 64,990 $807K
86665 <1% 44,276 $780K
87902 <1% 6,324 $773K
86364 <1% 51,691 $766K
87637 Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV <1% 7,045 $754K
82785 <1% 85,761 $740K
80349 <1% 128,498 $725K
86140 <1% 281,220 $721K
36415 Collection of venous blood by venipuncture <1% 1,166,399 $663K
86147 <1% 22,315 $645K
84479 <1% 266,211 $641K
83735 <1% 207,180 $629K
80321 <1% 85,563 $617K
88304 <1% 28,302 $594K
88141 <1% 48,903 $579K
87147 <1% 198,003 $561K
84270 <1% 53,326 $560K
80076 <1% 126,497 $544K
86160 <1% 46,288 $529K
83516 <1% 69,452 $526K
82274 <1% 73,587 $507K
86008 <1% 26,225 $497K
83021 <1% 47,069 $493K
87209 <1% 47,336 $490K
80348 <1% 91,311 $488K
83020 <1% 71,932 $485K
86146 <1% 16,979 $484K
83525 <1% 73,498 $474K
87650 <1% 45,016 $473K
82977 <1% 140,919 $464K
80354 <1% 88,536 $448K
85652 <1% 328,853 $445K
G0481 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed <1% 11,606 $434K
88342 <1% 9,573 $429K
86200 <1% 64,728 $426K
86225 <1% 62,626 $424K
81511 <1% 6,774 $418K
86431 <1% 135,417 $399K
84445 <1% 17,177 $398K
81596 <1% 12,764 $392K
87901 <1% 2,740 $386K
83521 <1% 10,908 $386K
81243 <1% 18,698 $380K
83498 <1% 24,817 $377K
84100 <1% 172,744 $372K
85610 <1% 196,926 $370K
82533 <1% 40,566 $368K
83615 <1% 129,450 $363K
86334 <1% 30,716 $362K
82378 <1% 40,060 $361K
84207 <1% 21,566 $346K
82550 <1% 110,529 $340K
86481 <1% 6,445 $335K
86255 <1% 35,521 $332K
87338 <1% 43,132 $330K
85730 <1% 129,174 $328K
84681 <1% 27,452 $326K
87563 <1% 18,421 $324K
86359 <1% 16,049 $319K
88230 <1% 5,355 $308K
83921 <1% 30,491 $305K
80346 <1% 61,414 $300K
88262 <1% 4,552 $300K
80362 <1% 62,631 $293K
86747 <1% 20,980 $293K
81229 <1% 1,813 $290K
86039 <1% 50,582 $287K
87255 <1% 16,721 $287K
83690 <1% 80,245 $286K
83880 <1% 19,969 $286K
86141 <1% 43,348 $277K
87177 <1% 47,314 $273K
82024 <1% 12,749 $269K
81003 <1% 245,003 $266K
86707 <1% 42,768 $260K
87350 <1% 46,237 $259K
87625 <1% 16,188 $257K
86709 <1% 41,261 $252K
80361 <1% 54,944 $249K
84305 <1% 20,869 $244K
80373 <1% 71,517 $243K
87427 <1% 35,743 $242K
86664 <1% 26,553 $232K
83993 <1% 22,347 $231K
87529 <1% 8,070 $229K
84425 <1% 24,481 $228K
88341 <1% 4,161 $222K
86666 <1% 14,098 $218K
81443 <1% 323 $218K
82465 <1% 97,343 $217K
86645 <1% 24,096 $215K
86258 <1% 10,878 $214K
86705 <1% 34,295 $212K
86901 <1% 122,808 $210K
82150 <1% 65,837 $210K
82157 <1% 12,675 $208K
84165 <1% 37,173 $205K
83090 <1% 22,552 $202K
86644 <1% 23,362 $195K
86753 <1% 17,183 $194K
87045 <1% 37,709 $194K
82950 <1% 76,007 $192K
86021 <1% 26,373 $192K
87449 <1% 32,534 $190K
86900 <1% 109,570 $183K
84156 <1% 100,704 $179K
80164 <1% 22,838 $179K
80358 <1% 42,540 $179K
87506 <1% 1,879 $179K
88121 <1% 787 $178K
80353 <1% 40,326 $177K
86300 <1% 15,644 $176K
88189 <1% 5,206 $174K
80371 <1% 22,976 $173K
86671 <1% 15,646 $173K
84703 <1% 45,352 $171K
G0483 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed <1% 2,519 $171K
82672 <1% 14,387 $169K
82088 <1% 7,852 $169K
86850 <1% 41,661 $167K
87497 <1% 8,495 $166K
84460 <1% 64,509 $161K
G0123 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, screening by cytotechnologist under physician supervision <1% 16,719 $160K
82107 <1% 4,731 $158K
86304 <1% 16,790 $158K
87329 <1% 22,061 $153K
82626 <1% 11,330 $152K
87900 <1% 2,527 $147K
82677 <1% 11,782 $145K
84432 <1% 19,447 $144K
88184 <1% 5,847 $142K
82542 <1% 12,251 $141K
82951 <1% 21,918 $139K
81401 <1% 2,926 $139K
80438 <1% 5,921 $138K
86355 <1% 7,100 $137K
86381 <1% 8,143 $134K
82985 <1% 18,986 $130K
86301 <1% 13,557 $130K
80197 <1% 19,677 $130K
87912 <1% 978 $130K
80324 <1% 27,200 $129K
86774 <1% 16,903 $128K
82565 <1% 56,259 $128K
86036 <1% 9,621 $125K
86738 <1% 9,091 $124K
86060 <1% 30,866 $123K
G0475 Hiv antigen/antibody, combination assay, screening <1% 9,820 $123K
G0124 Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, requiring interpretation by physician <1% 7,380 $123K
82310 <1% 51,124 $123K
86015 <1% 9,578 $122K
82947 <1% 66,108 $122K
86812 <1% 9,749 $121K
84450 <1% 57,319 $120K
88120 <1% 699 $120K
83519 <1% 12,289 $117K
86341 <1% 8,149 $116K
80365 <1% 28,696 $116K
81257 <1% 5,986 $115K
87906 <1% 1,476 $114K
86777 <1% 13,670 $110K
86361 <1% 8,457 $110K
87324 <1% 16,873 $103K
85045 <1% 52,265 $103K
85379 <1% 19,420 $102K
86335 <1% 6,754 $102K
82172 <1% 10,523 $101K
84466 <1% 15,450 $100K
86648 <1% 12,804 $100K
G0103 Prostate cancer screening; prostate specific antigen test (psa) <1% 13,554 $99K
82668 <1% 9,969 $96K
81206 <1% 2,345 $95K
86336 <1% 12,433 $94K
87150 <1% 9,838 $94K
84630 <1% 16,350 $93K
80355 <1% 57,200 $93K
82787 <1% 5,878 $93K
87493 <1% 5,540 $92K
88312 <1% 1,935 $91K
86757 <1% 4,935 $90K
87101 <1% 20,272 $89K
80323 <1% 19,026 $89K
86778 <1% 11,141 $88K
86215 <1% 11,761 $88K
87046 <1% 18,327 $88K
G0476 Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test <1% 9,540 $87K
83704 <1% 6,580 $87K
81382 <1% 2,297 $85K
82653 <1% 3,991 $84K
80159 <1% 8,636 $84K
84478 <1% 30,135 $83K
82747 <1% 9,770 $83K
G0328 Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous <1% 11,264 $83K
82040 <1% 41,044 $82K
81241 <1% 5,710 $81K
82164 <1% 10,755 $80K
86357 <1% 4,161 $80K
82166 <1% 3,335 $80K
83883 <1% 7,600 $79K
80178 <1% 20,165 $79K
84590 <1% 13,634 $78K
G0482 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed <1% 2,991 $78K
87075 <1% 15,418 $78K
85246 <1% 7,097 $78K
80360 <1% 14,937 $77K
82390 <1% 13,702 $76K
81207 <1% 2,236 $76K
80366 <1% 23,463 $75K
86870 <1% 5,180 $75K
84244 <1% 7,336 $75K
86593 <1% 32,025 $75K
88271 <1% 1,726 $74K
83698 <1% 4,269 $73K
82525 <1% 11,136 $73K
84520 <1% 45,080 $73K
86231 <1% 5,925 $71K
83721 <1% 40,018 $71K
85245 <1% 6,383 $70K
84182 <1% 1,515 $70K
80177 <1% 9,649 $67K
82530 <1% 6,004 $67K
84166 <1% 7,752 $66K
83695 <1% 10,924 $65K
85613 <1% 12,572 $65K
85240 <1% 7,589 $64K
83010 <1% 10,004 $64K
80069 <1% 16,346 $63K
84446 <1% 8,528 $63K
85018 <1% 53,689 $62K
84075 <1% 26,233 $62K
85041 <1% 38,375 $62K
85247 <1% 5,184 $61K
81508 <1% 2,660 $61K
87535 <1% 4,179 $61K
85660 <1% 21,796 $61K
84482 <1% 7,677 $58K
82103 <1% 8,178 $58K
87109 <1% 7,090 $57K
85014 <1% 48,614 $57K
87804 Infectious agent antigen detection by immunoassay; Influenza, each type <1% 3,813 $57K
82247 <1% 30,320 $56K
84378 <1% 9,017 $56K
80356 <1% 16,009 $56K
80374 <1% 12,643 $54K
86631 <1% 4,665 $53K
83835 <1% 5,976 $53K
86148 <1% 3,683 $53K
81240 <1% 4,179 $53K
80055 <1% 2,522 $52K
86256 <1% 3,379 $51K
80299 <1% 3,497 $50K
86162 <1% 4,684 $49K
80175 <1% 6,632 $49K
84163 <1% 6,467 $48K
87205 <1% 21,514 $48K
87254 <1% 3,163 $48K
82330 <1% 8,023 $47K
80368 <1% 12,277 $47K
82140 <1% 5,851 $47K
81376 <1% 2,400 $46K
80051 <1% 13,015 $46K
82397 <1% 6,549 $46K
83992 <1% 10,586 $46K
83003 <1% 3,974 $46K
84155 <1% 33,247 $46K
82955 <1% 8,507 $45K
85060 <1% 3,863 $45K
87880 Infectious agent antigen detection by immunoassay; Streptococcus, group A <1% 6,519 $44K
82180 <1% 8,757 $44K
81025 <1% 12,892 $43K
86340 <1% 5,276 $43K
86382 <1% 2,907 $42K
80352 <1% 8,749 $41K
85306 <1% 4,742 $41K
81279 <1% 1,589 $41K
86337 <1% 3,720 $40K
81256 <1% 2,753 $40K
81339 <1% 1,479 $39K
87467 <1% 2,130 $39K
87107 <1% 6,318 $39K
80357 <1% 32,721 $38K
83014 <1% 11,254 $37K
86702 <1% 5,816 $36K
87106 <1% 5,889 $36K
86632 <1% 4,636 $35K
80372 <1% 12,184 $35K
82952 <1% 18,022 $34K
84132 <1% 17,238 $34K
88275 <1% 683 $34K
86611 <1% 3,151 $33K
84252 <1% 3,723 $33K
84134 <1% 4,785 $33K
83825 <1% 3,965 $33K
81479 Unlisted molecular pathology procedure <1% 1,786 $33K
82232 <1% 4,494 $32K
80342 <1% 4,034 $32K
87800 <1% 1,348 $32K
82085 <1% 6,452 $31K
82308 <1% 2,497 $31K
81015 <1% 20,418 $30K
81270 <1% 2,794 $30K
86308 <1% 10,535 $30K
80320 <1% 9,441 $30K
85598 <1% 3,507 $30K
80338 <1% 7,054 $30K
85303 <1% 3,950 $29K
84255 <1% 2,411 $29K
80439 <1% 912 $28K
82610 <1% 4,080 $28K
G0472 Hepatitis c antibody screening, for individual at high risk and other covered indication(s) <1% 3,274 $28K
84295 <1% 16,219 $27K
83718 <1% 7,675 $27K
87102 <1% 5,802 $27K
80335 <1% 5,081 $27K
82507 <1% 1,704 $26K
80369 <1% 8,626 $26K
81512 <1% 785 $26K
86701 <1% 5,839 $26K
85004 <1% 8,763 $26K
82679 <1% 1,921 $26K
82384 <1% 1,892 $25K
87220 <1% 12,375 $25K
87040 <1% 4,604 $25K
86880 <1% 8,320 $25K
84597 <1% 3,406 $24K
80345 <1% 7,297 $24K
88313 <1% 595 $24K
82435 <1% 15,559 $23K
82175 <1% 2,228 $23K
80156 <1% 2,943 $23K
84484 <1% 4,087 $23K
0001M <1% 780 $23K
85384 <1% 4,918 $22K
85300 <1% 3,577 $21K
80364 <1% 8,163 $21K
81374 <1% 1,055 $21K
81219 <1% 1,571 $20K
86790 <1% 2,141 $20K
86682 <1% 2,584 $19K
82671 <1% 1,205 $19K
86692 <1% 1,870 $19K
86663 <1% 2,508 $19K
83951 <1% 589 $19K
84442 <1% 2,608 $18K
87116 <1% 3,223 $18K
87581 <1% 1,093 $18K
87469 <1% 1,145 $18K
86684 <1% 1,923 $18K
81291 <1% 2,546 $18K
80359 <1% 6,900 $16K
81162 <1% 42 $16K
99001 <1% 13,887 $16K
88274 <1% 745 $16K
87140 <1% 4,002 $16K
84591 <1% 2,844 $15K
83945 <1% 2,031 $15K
84560 <1% 5,651 $15K
87530 <1% 394 $15K
85048 <1% 11,362 $15K
80183 <1% 2,102 $15K
87484 <1% 954 $15K
82239 <1% 1,518 $14K
87468 <1% 893 $14K
84300 <1% 5,623 $14K
87252 <1% 834 $14K
86619 <1% 967 $14K
85305 <1% 2,073 $13K
87807 <1% 2,017 $13K
85597 <1% 1,407 $13K
82642 <1% 1,827 $13K
85007 <1% 7,734 $13K
82340 <1% 3,990 $13K
87206 <1% 4,561 $13K
84080 <1% 1,770 $13K
81400 <1% 413 $12K
87486 <1% 739 $12K
88307 <1% 120 $12K
80375 <1% 5,778 $12K
86161 <1% 1,737 $12K
87015 <1% 3,690 $12K
82657 <1% 682 $12K
82374 <1% 7,335 $11K
86609 <1% 1,243 $11K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 278 $11K
83630 <1% 1,099 $11K
82104 <1% 1,510 $11K
84140 <1% 1,000 $11K
80165 <1% 1,406 $11K
82731 <1% 285 $11K
81517 <1% 149 $11K
81381 <1% 284 $10K
83527 <1% 1,432 $10K
82139 <1% 1,024 $10K
87521 Neg quan hep c or qual rna <1% 453 $10K
83935 <1% 2,939 $10K
80185 <1% 1,440 $10K
86316 <1% 887 $10K
83625 <1% 1,552 $10K
80367 <1% 3,838 $9K
82552 <1% 1,363 $9K
86343 <1% 1,730 $9K
82365 <1% 1,406 $9K
85302 <1% 1,353 $9K
86356 <1% 461 $9K
84540 <1% 3,356 $9K
89055 <1% 3,876 $9K
81403 <1% 259 $9K
83874 <1% 1,414 $9K
82375 <1% 1,286 $8K
82705 <1% 2,998 $8K
84133 <1% 3,533 $8K
87328 <1% 1,251 $8K
U0002 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc <1% 176 $8K
85049 <1% 3,763 $7K
86658 <1% 169 $7K
81402 <1% 193 $7K
87425 <1% 997 $7K
82523 <1% 833 $7K
84143 <1% 492 $7K
83930 <1% 2,023 $7K
84238 <1% 467 $6K
86041 <1% 475 $6K
87341 <1% 1,442 $6K
87172 <1% 2,772 $6K
87207 <1% 1,588 $6K
87076 <1% 1,361 $6K
86886 <1% 2,093 $6K
80330 <1% 3,457 $6K
80337 <1% 3,167 $6K
84105 <1% 1,997 $6K
85307 <1% 702 $6K
80326 <1% 3,169 $6K
85250 <1% 514 $6K
86052 <1% 192 $6K
87185 <1% 1,916 $5K
88164 <1% 708 $5K
87634 <1% 165 $5K
87662 <1% 121 $5K
80332 <1% 3,404 $5K
80377 <1% 3,028 $5K
89060 <1% 1,182 $5K
80370 <1% 3,162 $5K
80158 <1% 573 $5K
80344 <1% 3,144 $5K
88300 <1% 1,416 $4K
82575 <1% 1,068 $4K
80333 <1% 3,123 $4K
80235 <1% 355 $4K
88237 <1% 49 $4K
80184 <1% 573 $4K
86596 <1% 195 $4K
83605 <1% 700 $4K
80340 <1% 3,026 $4K
86606 <1% 378 $4K
80327 <1% 119 $4K
82681 <1% 221 $4K
87272 <1% 497 $3K
88187 <1% 184 $3K
88264 <1% 41 $3K
80195 <1% 474 $3K
86703 <1% 569 $3K
86622 <1% 353 $3K
85670 <1% 1,007 $3K
86615 <1% 332 $3K
84066 <1% 698 $3K
86362 <1% 92 $3K
81364 <1% 43 $3K
85280 <1% 263 $3K
83631 <1% 281 $3K
89051 <1% 1,130 $3K
80162 <1% 495 $3K
83986 <1% 2,042 $3K
85270 <1% 268 $3K
82656 <1% 462 $3K
82108 <1% 174 $3K
81222 <1% 184 $2K
86788 <1% 257 $2K
80503 <1% 488 $2K
84392 <1% 921 $2K
82379 <1% 272 $2K
80201 <1% 350 $2K
86043 <1% 203 $2K
85301 <1% 349 $2K
82941 <1% 222 $2K
86023 <1% 274 $2K
86042 <1% 183 $2K
86789 <1% 239 $2K
88173 <1% 73 $2K
81327 <1% 80 $2K
80336 <1% 419 $2K
84260 <1% 106 $2K
87280 <1% 330 $2K
86001 <1% 420 $2K
0346U <1% 76 $2K
80426 <1% 26 $2K
81406 <1% 17 $2K
85097 <1% 42 $2K
86638 <1% 121 $2K
83088 <1% 93 $2K
87168 <1% 2,078 $1K
86366 <1% 133 $1K
87276 <1% 185 $1K
87275 <1% 185 $1K
83529 <1% 81 $1K
87300 <1% 241 $1K
87184 <1% 309 $1K
84311 <1% 895 $1K
85651 <1% 543 $1K
80180 <1% 131 $1K
88235 <1% 13 $1K
82595 <1% 340 $1K
81290 <1% 213 $1K
86710 <1% 69 $1K
83018 <1% 68 $930.60
86226 <1% 135 $924.52
84585 <1% 92 $881.20
80414 <1% 39 $796.52
87478 <1% 56 $786.65
86794 <1% 85 $784.27
84376 <1% 252 $771.75
87118 <1% 101 $723.58
86668 <1% 49 $711.84
85385 <1% 100 $648.84
89321 <1% 261 $627.54
83876 <1% 28 $596.84
82300 <1% 46 $577.21
83918 <1% 42 $575.37
85415 <1% 63 $571.44
87230 <1% 52 $562.03
82436 <1% 240 $553.04
88311 <1% 45 $502.36
80202 <1% 62 $466.37
86905 <1% 193 $464.11
82017 <1% 43 $415.35
80203 <1% 54 $410.33
80230 <1% 26 $407.13
88289 <1% 25 $405.04
83497 <1% 39 $318.24
80145 <1% 29 $312.31
82553 <1% 61 $300.14
84206 <1% 25 $273.05
84145 <1% 18 $268.40
87110 <1% 28 $257.83
81405 <1% 18 $241.58
81269 <1% 212 $196.64
P9604 Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge <1% 289 $196.61
81332 <1% 24 $190.59
83050 <1% 44 $185.36
87149 <1% 19 $180.25
G0306 Complete cbc, automated (hgb, hct, rbc, wbc, without platelet count) and automated wbc differential count <1% 116 $173.04
P3000 Screening papanicolaou smear, cervical or vaginal, up to three smears, by technician under physician supervision <1% 27 $165.00
86000 <1% 41 $157.79
81161 <1% 220 $151.36
82380 <1% 28 $144.98
82710 <1% 12 $132.55
86329 <1% 14 $118.55
86654 <1% 12 $108.51
84210 <1% 13 $86.93
84202 <1% 12 $79.98
86037 <1% 13 $64.27
87593 <1% 37 $50.00
83872 <1% 15 $39.14
82540 <1% 12 $32.48
99080 0% 17,459 $0.00
3051F 0% 3,596 $0.00
3050F 0% 16,958 $0.00
3046F 0% 2,493 $0.00
80301 0% 126 $0.00
85999 0% 14 $0.00
99199 Unlisted special service, procedure or report 0% 204 $0.00
3048F 0% 38,351 $0.00
3049F 0% 24,107 $0.00
3044F 0% 59,590 $0.00
3052F 0% 1,855 $0.00
99213 Doctor's office visit, returning patient (routine) 0% 1,849 $0.00
84999 0% 92 $0.00
G6056 Opiate(s), drug and metabolites, each procedure 0% 26 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialTIMMERMAN, LEAH (SR. VICE PRESIDENT)
Same official

Other billing entities under TIMMERMAN, LEAH

Full network →
ProviderLocationPaid
Unilab CorporationWest Hills, CA$668.50M
Quest Diagnostics LLC IlWood Dale, IL$429.84M
Quest Diagnostics Clinical Laboratories INCIrving, TX$276.76M
Labone LLCLenexa, KS$212.28M
Quest Diagnostics Clinical Laboratories INCTucker, GA$211.13M
Quest Diagnostics Clinical Laboratories INCMiramar, FL$197.58M
Labone of Ohio INCCincinnati, OH$167.17M
Unilab CorporationSacramento, CA$141.24M
Quest Diagnostics Incorporated MDBaltimore, MD$121.81M
Quest Diagnostics IncorporatedLas Vegas, NV$59.32M
Quest Diagnostics LLC IlSchaumburg, IL$50.71M
Quest Diagnostics Clinical Laboratories INCTampa, FL$49.99M
Quest Diagnostics Nichols Institute, INC.Chantilly, VA$46.91M
Quest Diagnostics Nichols InstituteSan Juan Capistrano, CA$39.93M
Quest Diagnostics Clinical Laboratories INCNorristown, PA$22.72M
Specialty Laboratories INCWest Hills, CA$16.76M
Quest Diagnostics Clinical Laboratories INCDenver, CO$14.27M
Quest Diagnostics Clinical Laboratories INCHouston, TX$8.76M
Med Fusion, LLCLewisville, TX$4.17M
Quest Diagnostics Clinical Laboratories INCMaryland Heights, MO$2.98M

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.